ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,John Allan, MD

Panelists discuss key factors in deciding between monotherapy and combination approaches for bispecific therapies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) as well as the potential for combination therapies to be more viable in certain B-cell lymphoma subtypes.

EP: 1.ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP: 2.Emerging Data for Odronextamab in DLBCL

EP: 3.Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

EP: 4.Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

Now Viewing

EP: 5.ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

Video content above is prompted by the following:

With several abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024 studying bispecific therapies in combination with conventional chemotherapy regimens, what factors should clinicians consider when deciding between monotherapy and combination approaches for bispecifics in FL and DLBCL?
Do you see combination therapies with bispecifics as more viable in certain subtypes of B-cell lymphoma compared with others? Why or why not?